These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35301096)

  • 21. In brief: A new indication for abemaciclib (Verzenio).
    Med Lett Drugs Ther; 2023 Apr; 65(1673):e62-e63. PubMed ID: 37020345
    [No Abstract]   [Full Text] [Related]  

  • 22. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    Palumbo A; Lau G; Saraceni M
    Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
    Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
    Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Tarantino P; Burstein HJ; Lin NU; Krop IE; Winer EP; Schnitt SJ; Hamilton EP; Hurvitz SA; Rugo HS; Curigliano G; Tolaney SM
    Ann Oncol; 2022 Mar; 33(3):234-238. PubMed ID: 34942341
    [No Abstract]   [Full Text] [Related]  

  • 26. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
    J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
    J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.
    Franzoi MA; Lambertini M; Ceppi M; Bruzzone M; de Azambuja E
    Breast Cancer Res Treat; 2022 Apr; 192(2):457-462. PubMed ID: 35076812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
    Tarantino P; Jin Q; Mittendorf EA; King TA; Curigliano G; Tolaney SM
    Ann Oncol; 2022 Aug; 33(8):845-847. PubMed ID: 35525374
    [No Abstract]   [Full Text] [Related]  

  • 30. Abemaciclib: First Global Approval.
    Kim ES
    Drugs; 2017 Dec; 77(18):2063-2070. PubMed ID: 29128965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer.
    Di Cosimo S; Porcu L; Cardoso F
    Breast; 2021 Feb; 55():75-78. PubMed ID: 33352521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
    JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
    O'Brien N; Conklin D; Beckmann R; Luo T; Chau K; Thomas J; Mc Nulty A; Marchal C; Kalous O; von Euw E; Hurvitz S; Mockbee C; Slamon DJ
    Mol Cancer Ther; 2018 May; 17(5):897-907. PubMed ID: 29483214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Inoue K; Masuda N; Iwata H; Takahashi M; Ito Y; Miyoshi Y; Nakayama T; Mukai H; van der Walt JS; Mori J; Sakaguchi S; Kawaguchi T; Tanizawa Y; Llombart-Cussac A; Sledge GW; Toi M
    Breast Cancer; 2021 Sep; 28(5):1038-1050. PubMed ID: 33797023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2- Early Breast Cancer.
    Oncologist; 2021 Feb; 26 Suppl 2(Suppl 2):S5-S6. PubMed ID: 33399254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding.
    Haynes HR; Mohan V; Mozayani B; Gallagher P
    Breast J; 2021 Jul; 27(7):612-614. PubMed ID: 33987967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib.
    Modi ND; Abuhelwa AY; Badaoui S; Shaw E; Shankaran K; McKinnon RA; Rowland A; Sorich MJ; Hopkins AM
    Breast; 2021 Aug; 58():57-62. PubMed ID: 33906086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
    Cuyun Carter G; Sheffield KM; Gossai A; Huang YJ; Zhu YE; Bowman L; Nash Smyth E; Mathur R; Cohen AB; Rasmussen E; Balakrishna S; Morato Guimaraes C; Rybowski S; Seidman AD
    Curr Med Res Opin; 2021 Jul; 37(7):1179-1187. PubMed ID: 33970738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.
    Badaoui S; Kichenadasse G; Rowland A; Sorich MJ; Hopkins AM
    Oncologist; 2021 Jul; 26(7):562-568. PubMed ID: 33914991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abemaciclib plus fulvestrant for breast cancer.
    Stirrups R
    Lancet Oncol; 2019 Nov; 20(11):e617. PubMed ID: 31587880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.